Additive manufacturing in pharmaceutical supply chain

dc.contributor.authorLi, Wenqi
dc.contributor.authorEkren, Banu Y.
dc.contributor.authorAktas, Emel
dc.date.accessioned2023-09-21T15:47:53Z
dc.date.available2023-09-21T15:47:53Z
dc.date.issued2023-09-08
dc.description.abstractPurpose: A resilient and efficient pharmaceutical supply chain (PSC) ensures access to essential medicines during pandemics and other emergencies. The COVID-19 pandemic has highlighted the need for continued investment and innovation in this area, and concerted efforts by all stakeholders are necessary to achieve this goal. Additive manufacturing (AM), or 3D printing, can enhance PSC resilience and performance, reduce waste, and improve environmental sustainability. 3D printing can help address drug shortages, patient-specific dosages, and personalised medicine in the pharmaceutical industry. Moreover, 3D printing technology enables local production of drugs and medical devices, reducing transportation costs, carbon footprint, and lead times, transforming how products are designed, produced, and delivered to end-users. This study aims to investigate the multifaceted benefits of 3D printing technology on the PSC, including its potential to streamline processes, increase SC efficiency, enhance responsiveness, and improve sustainability. Additionally, the study seeks to identify the interrelationships between these benefits and how they can contribute to the overall success of the PSC. Research Approach: To achieve this, we comprehensively analyse the potential benefits and shortcomings of 3D printing technology on the PSC by compiling relevant literature and internet sources. Findings and Originality: The study identifies ways in which 3D printing can positively impact the PSC, including simplifying the supply chain (SC) process, localising production, and transitioning from make-to-stock to make-to-order production. These changes can significantly impact inventory levels, increasing SC sustainability, efficiency, responsiveness, and resilience. However, this study also identifies unique shortcomings and future research opportunities associated with implementing 3D printing in the PSC, providing a holistic view of the technology's potential impact. Research Impact: The research highlights the potential of 3D printing to revolutionise the PSC by enabling a more streamlined and sustainable manufacturing process. Practical Impact: The study's findings offer the pharmaceutical industry insights on how to tackle SC shortcomings such as supplier shortages, fluctuating demand, and short response times. As a result, this study offers a valuable resource for both practitioners and researchers who wish to leverage 3D printing technology to enhance the PSC's performance and understand the technology's impact on the PSC.en_UK
dc.identifier.citationLi W, Ekren BY, Aktas E. (2023) Additive manufacturing in pharmaceutical supply chain. In: 27th Annual Conference of the Logistics Research Network (LRN) 2023, 6-8 September 2023, Edinburgh, Scotland, UKen_UK
dc.identifier.urihttps://ciltuk.org.uk/Events/National-Events-2023/Logistics-Research-Network-Conference
dc.identifier.urihttps://dspace.lib.cranfield.ac.uk/handle/1826/20270
dc.language.isoenen_UK
dc.publisherLogistics Research Network and CILTen_UK
dc.rightsAttribution-NonCommercial 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectAdditive manufacturingen_UK
dc.subjectmedical supply chainen_UK
dc.subject3D printing technologyen_UK
dc.subjectsupply chain resilienceen_UK
dc.subjectpharmaceutical supply chainen_UK
dc.titleAdditive manufacturing in pharmaceutical supply chainen_UK
dc.typeConference paperen_UK

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Additive_manufacturing_in_pharmaceutical_supply_chain-2023.pdf
Size:
216.21 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.63 KB
Format:
Item-specific license agreed upon to submission
Description: